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THE TRANSLATION AND LINGUISTIC VALIDATION OF
THE PAR-ENT-QOL QUESTIONNAIRE
Houchin C1, Taieb C2, Wild D1
1Oxford Outcomes Ltd, Oxford, UK, 2Pierre Fabre, Boulogne, France
OBJECTIVES: The PAR-ENT-QoL was developed in French. It is designed to assess
the effect on family life of children’s Rhinopharyngitis and otitis. This study’s ﬁ rst
objective was to produce a US English version to be used as the basis for other, con-
ceptually equivalent and culturally relevant, translations and then to perform these. 
METHODS: An unusual methodology was employed to create the US English version: 
2 translations into English, reconciliation by a bilingual native English consultant 
based in France, ‘back’ translations into French, back translation review, developer
review, cognitive debrieﬁ ng interviews with 5 members of the target population, 2 
proofreadings; with input at every stage from both consultants. The translations from 
English employed a standard methodology: 2 forward translations, reconciliation, 2
back translations, back translation review, or in-country review; developer review, 
cognitive debrieﬁ ng interviews as before, 2 proofreadings. RESULTS: Numerous cul-
tural and linguistic issues arose, some of them particular to this methodology: •In US 
English “Rhinopharyngitis” and “otitis” were not understood by the general popula-
tion so an explanation was added in the ﬁ rst instance. •Some in-country consultants 
were ﬂ uent in French so they worked directly from the English and used the French
version as a guide. •’Vous’ in French means ‘you’ but can be singular or plural. In the 
context this was translated as ‘you or your partner’. •The French ‘contrarié’ covers 
numerous English meanings including “upset” and “frustrated” – after developer 
input, ‘upset’ was used. CONCLUSIONS: The simplest way of performing transla-
tions from a non-English original questionnaire is to create an English version as a
basis for other translations. This now exists, and the PAR-ENT-QoL has been rigor-
ously translated and linguistically validated into 16 languages. A number of cultural
and linguistic issues became apparent and were resolved. The measure is now appro-
priate for use in multinational trials.
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THE IMPACT OF DISEASE ADAPTATION ON GENERAL
POPULATION VALUES
McTaggart-Cowan HM, Tsuchiya A, O’Cathain A, Brazier JE
University of Shefﬁ eld, Shefﬁ eld, South Yorkshire, UK
Health care resource allocation uses values for hypothetical health states elicited from
the general population rather than patient values. The drawback is that respondents
from the general population may not consider possible adaptation to the disease. This 
study aimed to investigate whether initial health state values change after the respon-
dents were informed about disease adaptation. Three rheumatoid arthritis (RA) states 
of different severities were used as a demonstration. METHODS: Participants (n 
156) were randomly allocated into two groups: Uninformed and Informed. Each group
completed two identical valuation tasks, consisting of rating and time trade-off (TTO)
exercises, and underwent an adaptation exercise (AE), where participants ﬁ rst listened 
to recordings of patients discussing how they adapted to RA and then were guided to 
reﬂ ect upon this information. The Uninformed Group valued the three states, under-
went the AE, and then completed a second set of valuations. The Informed Group 
started with the AE, then the ﬁ rst valuations; this was followed by a presentation of 
patient values of RA states and ﬁ nally a second set of valuations. RESULTS: For most 
health states, a statistically signiﬁ cant change between each pair of valuations was 
observed for both groups. For example, the TTO values of the Uninformed Group for 
the severe RA state were 0.24/0.49 and 0.43/0.52, while the Informed Group 
valued the same state at 0.33/0.52 and 0.41/0.51. This indicated that both the
AE and the patient values inﬂ uenced the valuations. When comparing the ﬁ rst TTO 
valuation of both groups, only the mild state showed a statistically signiﬁ cant differ-
ence (p  0.10). Speciﬁ cally, the Uninformed Group valued this state at 0.80/0.26 
whereas the Informed Group valued it at 0.87/0.20. CONCLUSIONS: The results
revealed that both the administration of the AE and the presentation of the patient
values informed the participants which, in turn, inﬂ uenced their valuations.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Study Design
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COMPARING CHART REVIEW AND MODIFIED DELPHI PANEL
RESOURCE DATA COLLECTION METHODS: THE COST OF TREATMENT
FOR MULTIPLE MYELOMA IN SWEDEN
Ghatnekar O1, Liwing J2, Löthgren M2, Aschan J2, Mellqvist UH3, Persson S1
1The Swedish Institute for Health Economics, Lund, Sweden, 2Janssen-Cilag AB, Sollentuna, 
Sweden, 3Sahlgrenska University Hospital, Gothenburg, Sweden
OBJECTIVES: Compare modiﬁ ed Delphi-panel survey methodology with a chart
review study on resource data collection and costing. METHODS: Results from a 
published chart review on the cost of treatment of multiple myeloma in Sweden
2001 – 2005 is compared with a modiﬁ ed Delphi-panel (2008) set up in accordance
to Evans et al. (1997, 2000). The panel consisted of four responding haematologists
at different university hospital clinics. Costs in year 2008 prices. RESULTS: Back-
ground patient characteristics differences between the chart review and Delphi-
panel were; gender: 3%, share aged above 65: 28%, mean number of co-morbidities
at diagnose: 6%, clinical trial participation: 383%. As expected, the treatment 
regimen options in 2008 had changed considerably since the chart review with the
introduction of thalidomide, bortezomib and lenalidomide, resulting in chemotherapy 
drugs representing the single greatest increase with Euro1164 (1013%). Consistent 
with the lower mean age in the Delphi-panel (68 vs. 76) stem cell transplantation
showed an increase with Euro698 (303%) and blood cell enhancing drugs with 
Euro471 (682%). Given the patient characteristics, we saw an expected moderate 
increase in costs for outpatient visits, laboratory- and diagnostic tests. Mean total 
cost per patient-month was estimated to Euro4800 in the Delphi panel, or 59%
higher than in the chart review. CONCLUSIONS: In therapeutic areas where treat-
ment practice is undergoing rapid changes and treatment guidelines are well accepted 
and complied with, expert opinions can be a valuable source to capture changes from 
a well-deﬁ ned but outdated baseline. However, the recruitment of representative 
respondents is important to avoid bias in patient selection and treatment practice. 
We believe our Delphi panel estimation of health care resource utilisation captures the
development of MM-treatment in Sweden since the results were in line with our
expectations on cost item development compared to the chart review given the patient
characteristics.
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AN EXPLORATORY ANALYSIS OF REASONS BEHIND PREMATURE
TERMINATION OF RANDOMIZED CONTROLLED TRIALS
Dimri S, Ubhadiya BS, Singh N, Narvilkar P, Bhanderi M
Heron Health Private Limited, Chandigarh, India
OBJECTIVES: The objective was to identify the reported factors leading to the 
premature termination of randomized controlled trials (RCTs). METHODS: A
clinical trial registry (clinicaltrials.gov) was searched on December 15, 2008 for iden-
tiﬁ cation of RCTs with recruitment status “terminated”. The RCTs submitted to 
the registry on or after January 1, 2004 were analyzed. Submission details were
reviewed to identify the reason for premature termination along with other study 
details. Reasons for termination were categorized according to the pre-speciﬁ ed 
categories. Descriptive statistics were used where appropriate. RESULTS: A total
of 1162 RCTs that met inclusion criteria were analyzed. Reason for premature
termination of trial was reported in 656 (56.45%) trials. The most frequent reasons
cited for the premature trial termination were: recruitment issues (244 trials), 
action based on interim analysis (68 trials), sponsor’s decision (63 trials), efﬁ cacy
related issues (44 trials) and safety concern (39 trials). These together were responsible
for premature termination of about 70% trials. Results of terminated trials were 
made available on the registry for only 144 (12.39%) trials. Sponsor’s decision was 
reported as responsible for the termination of twice as many trials during phase III or
IV compared to the earlier phase of development (13.5% vs. 6.5%). Out of the 78
large trials (estimated enrolment 500) reporting termination reasons, sponsor’s deci-
sion (24.4%) was the most frequent reason followed by action based on interim 
analysis (20.5%) and efﬁ cacy and safety related issues (11.5% each). CONCLU-
SIONS: Reporting of reasons for premature termination of RCTs was low with very 
few reporting the results on the registry. Slow recruitment and results of interim analy-
sis were the major factors contributing to premature termination of RCTs, where
reasons were reported.
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MANAGING STUDY PARTICIPANT RECRUITMENT SITES: METHODS
FOR OPTIMIZING SUBJECT RECRUITMENT AND RETENTION
THROUGH PRIVATE PRACTICE OFFICES
Schoenberger C, Ruetsch C
Health Analytics, LLC, Columbia, MD, USA
Recruiting study subjects via private physician ofﬁ ces is a common research practice 
because such sites offer several beneﬁ ts, including existing infrastructure and patient
volume. Yet researchers face many challenges with achieving a sufﬁ cient sample size
and retaining subjects when managing multiple physician ofﬁ ces as a study sites. Many 
physician ofﬁ ces lack the resources to manage the administrative workload associated 
with subject recruitment and retention. There are strategies researchers can employ to 
optimize recruitment and retention efforts when contracting with multiple physician 
ofﬁ ces. We launched a study in October 2008 to examine outpatient treatment out-
comes among a sample of patients seeking treatment for opioid dependence. In order 
to achieve a sample size of 2000 patients, we targeted several hundred physicians
across the United States that have been certiﬁ ed by the DEA to prescribe buprenor-
phine. A variety of methods were used to maximize study enrollment. Study site physi-
cians were required to attend training about the study and received written training 
materials. Initially, online informed consent was required. However, paper-based
informed consent options were added during the recruitment period to accommodate
ofﬁ ces without internet access. Furthermore, we offered to provide these ofﬁ ces with 
internet-equipped laptops so patients could enroll at the time of their ofﬁ ce visit. 
Physicians received a bi-weekly progress report detailing enrollment status for the
study as a whole and for individual study sites. Repeated, targeted outreach to physi-
cians with zero or few patients enrolled was conducted. As a result of these efforts, 
we were able to meet study recruitment goals. Groups that conduct clinical trials or
other patient outcomes studies will beneﬁ t from employing similar strategies when
managing multiple physician sites for subject recruitment and retention.
